COMPANY

ImaginAb

HQ: Calabasas, CA source · imaginab.com ↗ · West Coast

Keywords: antibody Melanoma Renal Cell Carcinoma Positron-Emission Tomography Prostate Cancer Unspecified Merkel Cell Carcinoma Non Small Cell Lung Cancer Metastatic Prostate Cancer Immunomodulation Hodgkin Lymphoma [89Zr]Df-IAB2M Zirconium 89Zr crefmirlimab berdoxam zirconium Zr 89 crefmirlimab berdoxam ⁸⁹Zr-Df-IAB22M2C

Location: Calabasas, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

7Trials (company is sponsor)

Timeline

Feb 16, 2023 Trial start Phase 2: CD8 Minibody Repeatability Study source ↗
Dec 9, 2021 Trial start Phase 2: Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies source ↗
Dec 18, 2018 Trial start Phase 2: ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors source ↗
Jun 19, 2017 Trial start Phase 1: ⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma source ↗
2015-03 Trial start Phase 2: A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer source ↗
2015-01 Trial start Phase 2: Comparison of PET With [89Zr]-Df-IAb2M and [111In]-Capromab Pendetide in the Detection of Prostate Cancer Pre-Prostatectomy source ↗
2013-08 Trial start I: Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer source ↗

Clinical trials (lead sponsor) 7

Record	Title	Phase	Status	Start	Primary completion
NCT05744128	CD8 Minibody Repeatability Study	Phase 2	Terminated	Feb 16, 2023	May 31, 2024 (actual)
NCT05013099	Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies	Phase 2	Unknown status (ClinicalTrials.gov)	Dec 9, 2021	2025-07 (estimated)
NCT03802123	⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors	Phase 2	Completed	Dec 18, 2018	Oct 19, 2021 (actual)
NCT01923727	Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer	I	Completed	2013-08	2016-05 (actual)
NCT02349022	Comparison of PET With [89Zr]-Df-IAb2M and [111In]-Capromab Pendetide in the Detection of Prostate Cancer Pre-Prostatectomy	Phase 2	Completed	2015-01	2016-04 (actual)
NCT03107663	⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma	Phase 1	Completed	Jun 19, 2017	Aug 16, 2018 (actual)
NCT02424513	A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer	Phase 2	Withdrawn	2015-03	2016-03 (estimated)